Megetra 40 Tablet contains Megestrol acetate 40 mg, a synthetic progestin used primarily in the management of anorexia, cachexia, and unexplained weight loss in patients with chronic illnesses such as cancer and acquired immunodeficiency syndrome (AIDS). Megestrol acts by stimulating appetite and promoting weight gain through its progestogenic and antineoplastic properties. It is also employed as an adjunctive therapy in hormone-responsive cancers, including breast and endometrial carcinoma, due to its ability to inhibit the secretion of pituitary gonadotropins, thereby reducing estrogen production. Megetra 40 is administered orally and should be used under strict medical supervision, with dosage tailored according to the clinical condition and patient response. Common adverse effects may include fluid retention, thromboembolic events, hypertension, and gastrointestinal disturbances. Caution is advised in patients with a history of cardiovascular disease, diabetes, or thromboembolic disorders. Regular monitoring of weight, blood pressure, and metabolic parameters is recommended during therapy. Contraindications include known hypersensitivity to Megestrol or any component of the formulation, pregnancy, and active thromboembolic disease. Megetra 40 Tablet offers a valuable therapeutic option for improving quality of life in patients experiencing significant weight loss and for managing hormone-dependent malignancies.